SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Angion Biomedica Corp. (ANGN) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+50%).
- Analyst consensus target $1.50 (+50% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 44/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ANGN
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-2.58
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$1.50 (+50%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2012 |
$0.02 |
$7.3M |
$307.3K |
4.2% |
| 2013 |
$0.04 |
$6.58M |
$632.24K |
9.6% |
| 2018 |
$-1.30 |
$4.03M |
$-20.03M |
-497% |
| 2019 |
$-2.51 |
$1.49M |
$-42.37M |
-2849% |
| 2020 |
$-2.76 |
$2.88M |
$-79.48M |
-2759.7% |
| 2021 |
$-1.90 |
$28.31M |
$-53.77M |
-189.9% |
| 2022 |
$-1.85 |
$2.3M |
$-55.7M |
-2420.7% |
| 2024 |
$-4.25 |
$0.00 |
$-51.9M |
- |
| 2025 |
$-2.58 |
$0.00 |
$-39.57M |
- |
